

EYEPOINT PHARMACEUTICALS, INC.
480 Pleasant Street
Watertown, MA 02472

October 26, 2023

VIA EDGAR

Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jane Park

Re: EyePoint Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed October 20, 2023
File No. 333-275125
Request for Acceleration of Effective Date

Dear Jane Park:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, EyePoint Pharmaceuticals, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on October 30, 2023, or as soon thereafter as possible.

Please direct any questions or comments concerning this request to Stephen M. Nicolai of Hogan Lovells US LLP at (267) 675-4642. Also, please notify Mr. Nicolai when this request for acceleration has been granted.

Very truly yours,

EyePoint Pharmaceuticals, Inc.

By: /s/ Ron Honig

Name: Ron Honig

Title: Chief Legal Officer